Skip to content

About Us
Our Science
Media
Pipeline
- Overview
- AWARE-1
- BRACELET-1
- GOBLET
Investors
- Overview
- News
- Events
- Stock Information
- Filings
- Corporate Governance
- FAQs
Careers
Contact

About Us
Our Science
Media
Pipeline
- Overview
- AWARE-1
- BRACELET-1
- GOBLET
Investors
- Overview
- News
- Events
- Stock Information
- Filings
- Corporate Governance
- FAQs
Careers
Contact

About Us
Our Science
Media
Pipeline
- Overview
- AWARE-1
- BRACELET-1
- GOBLET
Investors
- Overview
- News
- Events
- Stock Information
- Filings
- Corporate Governance
- FAQs
Careers
Contact

About Us
Our Science
Media
Pipeline
- Overview
- AWARE-1
- BRACELET-1
- GOBLET
Investors
- Overview
- News
- Events
- Stock Information
- Filings
- Corporate Governance
- FAQs
Careers
Contact

News

Select Year
Clinical Trials
Search …

September 30, 2008

Oncolytics Biotech Inc. Announces Issuance of 28th U.S. Patent

September 22, 2008

Oncolytics Biotech Inc. Collaborators to Present REOLYSIN(R) Clinical Trial

September 8, 2008

Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin

September 2, 2008

Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours

September 2, 2008

/R E P E A T — Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/

July 14, 2008

Oncolytics Biotech Inc. Treats 200th Cancer Patient in Clinical Studies with REOLYSIN(R)

June 20, 2008

Oncolytics Biotech Inc. Announces U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin

June 12, 2008

Oncolytics Biotech Inc. to Present at BIO 2008 International Convention

June 10, 2008

Oncolytics Biotech Inc. Announces Start of Enrolment in Phase 1/2 Ovarian Cancer Clinical Trial with REOLYSIN(R)

June 5, 2008

Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin

Page 61 of 69

Investor Relations Contact

Jon Patton
Director of Investor Relations & Communication
Email: jpatton@oncolytics.ca

Email Alerts Sign-Up

Email

I accept the Privacy Policy

Loading...

4350 Executive Drive
Suite 325
San Diego, CA 92121
info@oncolyticsbiotech.com

Company

About Us
Leadership
Scientific Advisors
Careers
Contact

Science

Our Science
Pipeline
Publications

Investors

Overview
News
Events
Stock Information
Filings
Corporate Governance
FAQs

Privacy Policy Accessibility Cookie Policy Disclaimer Sitemap Manage Consent

Copyright © 2025 Oncolytics Biotech Inc.